Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: New Guidelines: HIV Exposure at Work, Treat ASAP


MedPage Today (08.09.2013)

The US Public Health Service (USPHS) has issued updated guidelines for managing healthcare workers’ occupational exposure to HIV. Under these guidelines, healthcare workers exposed to HIV should begin treatment immediately with four weeks of post-exposure prophylaxis (PEP) with three antiretroviral drugs. This is a change from the 2005 recommendations, which suggested that the number of drugs should be based on assessment of the risk of infection. According to CDC’s David Kuhar, MD, and colleagues, earlier recommendations presented a challenge because of difficulty determining risk levels. USPHS left in place some of the old guidelines, including PEP where there is occupational exposure; investigation of HIV status of the source to determine whether PEP is necessary; immediate initiation of treatment that should last four weeks; consultation with HIV experts, particularly in complicated cases such as exposure of pregnant women, suspicion of HIV drug resistance in the source, or serious underlying illness of the exposed worker; and close follow-up with initial counseling, baseline, and follow-up testing and monitoring 72 hours after exposure. The new recommendations shortened follow-up testing from six months to four months with the use of a fourth-generation test, as newer tests detect the HIV p24 antigen and antibodies to the virus and are more reliable than previous tests. It also recommended a preferred initial regimen—a combination of tenofovir and emtricitabine with raltegravir—because that regimen has a convenient dosing schedule and favorable side effects. However, those undergoing treatment still require expert consultation to adapt the treatment to the exposed individual. The full report, “Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis,” was published online in the journal Infection Control and Hospital Epidemiology (2013; doi: 10.1086/672271).


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in August 12, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.